BioSpace News Archive

Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or NMPA) issued a product license for its quadrivalent Influenza vaccine (or QIV).

RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced it plans to hold a business update call, and in conjunction release financial and operating results for the quarter ended March 31, 2020, on Tuesday, June 30, 2020, prior to the market open.

While studying the genetics of the androgen receptor in male pattern baldness, a team of scientists discovered a possible breakthrough treatment for COVID-19.

Doheny Eye Institute has announced that Stephen A. Ralph now serves as a member of the DEI Board of Directors after being elected to the position on March 31st.

RemedyOne, a formulary optimization company focused on making systems work, is leading the charge to increase member access to prescription digital therapeutics (PDTs) to help fight the current public health crises of substance use disorder (SUD) and opioid use disorder (OUD) as people are impacted by COVID-19 and social distancing reSET and reSET-O will be made available as a covered benefit to RemedyOne’s customer base of 2.5 million lives

Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, today announced that its flagship biofungicide, Regalia, holds more than 25% market share* of the foliar biofungicide segment in California; outperforming direct competitors during January through April 2020. “Regalia’s performance is a testament to its efficacy for managing plant diseases and improving crop heal

Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models

ALRT Partners with Bionime Corporation to Offer Comprehensive Diabetes Solution at Lower Cost Than Test Supplies Alone Available in Pharmacy Chains

DelMar Pharmaceuticals Receives $500,000 Loan from the NBTS and NFCR to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of up to 900,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $1,000,000 USD (approximately $1,350,000 CAD) (the “Offering”). The proceeds of